感染症診断・検査製品の世界市場:感染症検査試薬、検査キット、診断機器、アナライザー

【英語タイトル】Infectious Disease Diagnostics Market by Product (Instruments, Reagents, Services, Software), Application (Hepatitis C, AIDS, Tuberculosis), Technology (PCR, INAAT, DNA Sequencing, Hybridization), End User (Hospital, Laboratories) - Global Forecast to 2019

MarketsandMarketsが出版した調査資料(MAM-MD-3088)・商品コード:MAM-MD-3088
・発行会社(調査会社):MarketsandMarkets
・発行日:2015年1月8日
・ページ数:210
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、感染症診断・検査製品の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、市場シェア分析、製品別分析、用途別分析、技術別分析、地域別分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

Increasing Prevalence of Deadly Infectious Disease and Need For Highly Specific and Sensitive Technologies for Rapid Diagnosis to Drive Growth of the IDD Market
The global IDD market report is segmented by product, application, technology, end user, and region. The immunodiagnostics and polymerase chain reaction technology segments accounted for the lion’s share of the global IDD market by technology, owing to growing need for advanced technologies for rapid diagnosis of infectious diseases.
On the basis of application, the IDD market is categorized into the Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), human papillomavirus (HPV), methicillin-resistant Staphylococcus aureus (MRSA), and others (Influenza, Ebola, Typhoid, Malaria, and Dengue, among others). Hospital-acquired MRSA infections, human papillomavirus, and AIDS are expected to be new revenue pockets in the applications market. The rising prevalence of these diseases globally is the major factor driving the growth of the aforementioned markets.

On the basis of product, the IDD market is segmented into instruments, consumables (reagents and assays), and software & services. Among products, consumables are estimated to be the fastest-growing market owing to its growing adoption in emerging infectious disease diagnostics worldwide.
On the basis of end user, the market is segmented into hospital laboratories, reference labs, physician’s office labs, academics, and others (blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing). Hospital laboratories are expected to be the fastest-growing market in the forecast period. Owing to the complexity and highly specialized nature of diagnostic tests for infectious diseases, hospital laboratories are expected to grow at the fastest rate in the forecast period, from 2014 to 2019.

From an insight perspective, this report focuses on qualitative data, market size, and the growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), winning imperatives, and burning issues. The report also offers market sizes and related growth of various segments in the industry. It focuses on emerging and high-growth segments of the IDD market, high-growth regions, and initiatives of respective governments. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles offer basic views on key players in the IDD market and their product portfolios, recent developments, and key strategies adopted. The abovementioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, approaches, R&D investments for innovations in products and technologies, and levels of output, in order to remain successful.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 19
1.3 MARKETS SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 MARKET SIZE ESTIMATION 23
2.1.1 KEY DATA FROM SECONDARY SOURCES 27
2.1.2 KEY DATA FROM PRIMARY SOURCES 27
2.1.3 KEY INDUSTRY INSIGHTS 28
2.1.4 ASSUMPTIONS 28

3 EXECUTIVE SUMMARY 29

4 PREMIUM INSIGHTS 35
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET 35
4.2 INFECTIOUS DISEASE DIAGNOSIS MARKET SNAPSHOT 36
4.3 LUCRATIVE GROWTH OPPORTUNITIES IN APAC 37
4.4 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 37
4.5 LIFE CYCLE ANALYSIS, BY REGION 38
4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT 38
4.7 IDD MARKET, BY END USER 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 41
5.1.1 EVOLUTION 41
5.1.2 MARKET SEGMENTATION 42
5.2 MARKET DYNAMICS 42
5.2.1 DRIVERS 43
5.2.1.1 High prevalence rate of infectious diseases 43
5.2.1.2 Slow turnaround time of the current diagnostic cycle creating demand for rapid diagnostic procedures 44

5.2.1.3 New rapid diagnostic tests hold promise for improved management and control of infectious diseases 44
5.2.1.4 Growth in funding for research on infectious disease diagnostics 44
5.2.2 RESTRAINTS 45
5.2.2.1 Rising healthcare costs limiting the usage of novel infectious disease diagnostic techniques 45
5.2.2.2 Complex regulatory framework to delay approvals of new diagnostic tests 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Huge growth prospects in developing countries 46
5.2.3.2 Advances in research and development for better diagnostic procedures 46
5.2.3.3 Personalized Medicine 47
5.2.4 CHALLENGES 47
5.2.4.1 Dearth of trained professionals limiting the appropriate use of new diagnostic tests 47
5.2.4.2 Limited reimbursement for new diagnostic tests may hamper innovation 48
5.2.5 WINNING IMPERATIVE 48
5.2.5.1 Shift in focus from centralized laboratories to decentralized point-of-care testing augmenting the growth of the IDD market 48
5.2.6 BURNING ISSUE 49
5.2.6.1 Global regulatory environment limiting the clearance and marketing of infectious disease diagnostic products 49

6 INDUSTRY INSIGHTS 50
6.1 INTRODUCTION 50
6.2 STRATEGIC BENCHMARKING 50
6.3 PEST ANALYSIS 51
6.3.1 POLITICAL FACTORS 51
6.3.2 ECONOMIC FACTORS 51
6.3.3 SOCIO-CULTURAL FACTORS 51
6.3.4 TECHNOLOGICAL FACTORS 52
6.4 SUPPLY CHAIN 52
6.4.1 KEY INFLUENCERS 53
6.5 INDUSTRY INSIGHTS 53

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT 54
7.1 INTRODUCTION 55
7.2 CONSUMABLES 56
7.2.1 ASSAYS & REAGENTS 57
7.3 INSTRUMENTS & ANALYZERS 59
7.3.1 INTRODUCTION 59
7.3.2 INSTRUMENTS (OTHER THAN ANALYZERS) 59
7.4 ANALYZERS 61
7.5 SERVICES & SOFTWARE 62

8 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY APPLICATION 64
8.1 INTRODUCTION 65
8.2 HEPATITIS B 66
8.3 HEPATITIS C 68
8.4 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 69
8.5 TUBERCULOSIS (TB) 71
8.6 CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) INFECTION 73
8.7 HUMAN PAPILLOMAVIRUS (HPV) INFECTION 74
8.8 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIONS 76
8.9 OTHER INFECTIONS 78

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY 80
9.1 INTRODUCTION 81
9.2 TRADITIONAL DIAGNOSTIC TECHNOLOGIES 83
9.2.1 IMMUNODIAGNOSTICS 83
9.2.2 BIOCHEMICAL CHARACTERIZATION 85
9.2.3 MICROSCOPY 86
9.3 MOLECULAR DIAGNOSTIC TECHNOLOGIES 88
9.3.1 POLYMERASE CHAIN REACTION (PCR) 88
9.3.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 91
9.3.3 IN SITU HYBRIDIZATION 93
9.3.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 94
9.3.5 MICROARRAYS 96
9.3.6 OTHERS 99

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER 101
10.1 INTRODUCTION 102
10.2 HOSPITAL LABORATORIES 103
10.3 REFERENCE LABORATORIES 105
10.4 PHYSICIANS’ OFFICE LABORATORIES 107
10.5 ACADEMIC INSTITUTE LABORATORIES 108
10.6 OTHER END USERS 109

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY GEOGRAPHY 112
11.1 INTRODUCTION 113
11.2 NORTH AMERICA 115
11.2.1 U.S. 122
11.2.2 CANADA 126

11.3 EUROPE 130
11.3.1 GERMANY 135
11.3.2 U.K. 135
11.3.3 REST OF EUROPE (ROE) 136
11.4 ASIA-PACIFIC 136
11.5 REST OF THE WORLD (ROW) 142

12 COMPETITIVE LANDSCAPE 146
12.1 OVERVIEW 146
12.2 MARKET SHARE ANALYSIS, GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET 147
12.3 NEW PRODUCT LAUNCHES 148
12.3.1 AGREEMENTS & PARTNERSHIPS 153
12.3.2 ACQUISITIONS 156
12.3.3 EXPANSIONS 157
12.3.4 OTHER DEVELOPMENTS 158

13 COMPANY PROFILES 162
13.1 INTRODUCTION 162
13.2 ABBOTT LABORATORIES 163
13.3 BECTON, DICKINSON & CO. 167
13.4 BIOMÉRIEUX 174
13.5 BIO-RAD LABORATORIES 179
13.6 ALERE, INC. 182
13.7 THERMO FISHER SCIENTIFIC, INC. 188
13.8 SIEMENS HEALTHCARE 193
13.9 ROCHE DIAGNOSTICS 196
13.10 DANAHER CORPORATION 199
13.11 JOHNSON & JOHNSON 201
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

14 APPENDIX 203
14.1 INSIGHTS OF INDUSTRY EXPERTS 203
14.2 DISCUSSION GUIDE 204
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 207
14.4 AVAILABLE CUSTOMIZATIONS 208
14.5 RELATED REPORTS 209

LIST OF TABLES

TABLE 1 HIGH PREVALENCE RATE OF INFECTIOUS DISEASES AND DEVELOPMENT OF NEW RAPID DIAGNOSTIC TESTS LIKELY TO PROPEL IDD MARKET GROWTH 45
TABLE 2 INCREASING HEALTHCARE COST AND STRINGENT REGULATORY FRAMEWORK ARE RESTRAINING THE GROWTH OF THE IDD MARKET 46
TABLE 3 PERSONALIZED MEDICINE IS EXPECTED TO PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES FOR THE IDD MARKET 47
TABLE 4 REIMBURSEMENT ISSUES ARE A MAJOR CHALLENGE IN THE IDD MARKET 48
TABLE 5 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 55
TABLE 6 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CONSUMABLES,
BY REGION, 2012–2019 ($MILLION) 56
TABLE 7 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CONSUMABLES, BY COUNTRY, 2012–2019 ($MILLION) 58
TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INSTRUMENTS & ANALYZERS, BY REGION, 2012–2019 ($MILLION) 59
TABLE 9 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2012–2019 ($MILLION) 61
TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR SERVICES & SOFTWARE,
BY REGION, 2012–2019 ($MILLION) 63
TABLE 11 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR SERVICES & SOFTWARE, BY COUNTRY, 2012–2019 ($MILLION) 63
TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 66
TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS B, BY REGION, 2012–2019 ($MILLION) 67
TABLE 14 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS B, BY COUNTRY, 2012-2019 ($MILLION) 67
TABLE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS C, BY REGION,
2012–2019 ($MILLION) 69
TABLE 16 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HEPATITIS C, BY COUNTRY, 2012–2019 ($MILLION) 69
TABLE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR AIDS, BY REGION,
2012–2019 ($MILLION) 71
TABLE 18 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR AIDS,
BY COUNTRY, 2012–2019 ($MILLION) 71
TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TB, BY REGION,
2012–2019 ($MILLION) 72
TABLE 20 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TB,
BY COUNTRY, 2012–2019 ($MILLION) 72
TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CT/NG INFECTIONS,
BY REGION, 2012–2019 ($MILLION) 73
TABLE 22 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR CT/NG INFECTIONS, BY COUNTRY, 2012–2019 ($MILLION) 74
TABLE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HPV INFECTIONS,
BY REGION, 2012–2019 ($MILLION) 75
TABLE 24 NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HPV INFECTIONS, BY COUNTRY, 2012–2019 ($MILLION) 76
TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MRSA INFECTIONS,
BY REGION, 2012–2019 ($MILLION) 77
TABLE 26 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MRSA INFECTIONS, BY COUNTRY, 2012–2019 ($MILLION) 78
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER INFECTIONS,
BY REGION, 2012–2019 ($MILLION) 79
TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 83
TABLE 29 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IMMUNODIAGNOSTICS,
BY REGION, 2012–2019 ($MILLION) 84
TABLE 30 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2012–2019 ($MILLION) 84
TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR BIOCHEMICAL CHARACTERIZATION, BY REGION, 2012–2019 ($MILLION) 85
TABLE 32 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR BIOCHEMICAL CHARACTERIZATION, BY COUNTRY, 2012–2019 ($MILLION) 85
TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROSCOPY, BY REGION, 2012–2019 ($MILLION) 87
TABLE 34 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROSCOPY, BY COUNTRY, 2012–2019 ($MILLION) 87
TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PCR, BY REGION,
2012–2019 ($MILLION) 90
TABLE 36 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PCR,
BY COUNTRY, 2012–2019 ($MILLION) 91
TABLE 37 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INAAT, BY REGION,
2012–2019 ($MILLION) 92
TABLE 38 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR INAAT, BY COUNTRY, 2012–2019 ($MILLION) 93
TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION,
BY REGION, 2012–2019 ($MILLION) 94
TABLE 40 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2012–2019 ($MILLION) 94
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR DNA SEQUENCING & NGS, BY REGION, 2012–2019 ($MILLION) 96
TABLE 42 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR DNA SEQUENCING & NGS, BY COUNTRY, 2012–2019 ($MILLION) 96
TABLE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY REGION, 2012–2019 ($MILLION) 98
TABLE 44 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MICROARRAYS, BY COUNTRY, 2012–2019 ($MILLION) 98
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES,
BY REGION, 2012–2019 ($MILLION) 99
TABLE 46 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES, BY COUNTRY, 2012–2019 ($MILLION) 100
TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 102
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HOSPITAL LABORATORIES, BY REGION, 2012–2019 ($MILLION) 104
TABLE 49 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR HOSPITAL LABORATORIES, BY COUNTRY, 2012–2019 ($MILLION) 105
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY REGION, 2012–2019 ($MILLION) 105
TABLE 51 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2012–2019 ($MILLION) 106
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PHYSICIANS’ OFFICE LABORATORIES, BY REGION, 2012–2019 ($MILLION) 107
TABLE 53 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR PHYSICIANS’ OFFICE LABORATORIES, BY COUNTRY , 2012–2019 ($MILLION) 107
TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR ACADEMIC INSTITUTE LABORATORIES, BY REGION, 2012–2019 ($MILLION) 108
TABLE 55 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR ACADEMIC INSTITUTE LABORATORIES, BY COUNTRY, 2012–2019 ($MILLION) 109
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY REGION, 2012–2019 ($MILLION) 110
TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2012–2019 ($MILLION) 111
TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION,
2012–2019 ($MILLION) 114
TABLE 59 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) 118
TABLE 60 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE,
BY TECHNOLOGY, 2012–2019 ($MILLION) 119
TABLE 61 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 119
TABLE 62 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 120
TABLE 63 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION) 121
TABLE 64 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE,
BY APPLICATION, 2012–2019 ($MILLION) 121
TABLE 65 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE,
BY END USER, 2012–2019 ($MILLION) 122
TABLE 66 U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 123
TABLE 67 U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 123
TABLE 68 U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 124
TABLE 69 U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 124
TABLE 70 U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 125
TABLE 71 U.S.: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 126
TABLE 72 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION) 127
TABLE 73 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 127
TABLE 74 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 128
TABLE 75 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 128
TABLE 76 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION) 129
TABLE 77 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 129
TABLE 78 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION) 132
TABLE 79 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 132
TABLE 80 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 133
TABLE 81 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 133
TABLE 82 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION) 134
TABLE 83 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 134
TABLE 84 ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2012–2019 ($MILLION) 138
TABLE 85 ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 138
TABLE 86 ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 139
TABLE 87 ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION) 140
TABLE 88 ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2012–2019 ($MILLION) 141
TABLE 89 ASIA-PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2012–2019 ($MILLION) 141
TABLE 90 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012–2019 ($MILLION) 143
TABLE 91 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 143
TABLE 92 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2012–2019 ($MILLION) 144
TABLE 93 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 144
TABLE 94 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 145
TABLE 95 ROW: INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 145
TABLE 96 NEW PRODUCT LAUNCHES, 2011–2014 149
TABLE 97 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS, 2011–2014 153
TABLE 98 ACQUISITION, 2011–2014 156
TABLE 99 EXPANSION, 2011–2014 157
TABLE 100 OTHER DEVELOPMENTS, 2011–2014 158


LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 22
FIGURE 2 MARKET SIZE ESTIMATION METHODOLOGY 24
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
FIGURE 4 MARKET BREAKDOWN AND DATA TRIANGULATION 26
FIGURE 5 IMMUNODIAGNOSTICS WILL GROW AT THE HIGHEST RATE IN THE NEXT FIVE YEARS 29
FIGURE 6 IDD MOLECULAR DIAGNOSTICS MARKET SIZE SNAPSHOT (2014 VS. 2019): MICROARRAYS WILL GROW AT THE HIGHEST RATE IN THE NEXT FIVE YEARS 30
FIGURE 7 GLOBAL IDD MARKET SIZE, BY APPLICATION, 2014 31
FIGURE 8 HOSPITAL LABORATORIES EXPECTED TO BE FASTEST GROWING SEGMENT IN 2014–2019 32
FIGURE 9 ASIA-PACIFIC EXPECTED TO BE THE FASTEST-GROWING MARKET DURING THE FORECAST PERIOD 33
FIGURE 10 NEW PRODUCT LAUNCHES IS THE DOMINANT STRATEGY ADOPTED BY THE MARKET PLAYERS DURING THE FORECAST PERIOD 34
FIGURE 11 GROWING PERSONALIZED MEDICINE AND ADVANCEMENTS IN R&D WILL DRIVE MARKET GROWTH 35
FIGURE 12 NORTH AMERICA CONTINUES TO HOLD MAXIMUM MARKET SHARE OF INFECTIOUS DISEASE DIAGNOSTICS MARKET 36
FIGURE 13 ASIA-PACIFIC TO GROW AT THE HIGHEST PACE DURING THE FORECAST PERIOD 37
FIGURE 14 HIGH GROWTH POTENTIAL IN THE ASIA-PACIFIC IDD TECHNOLOGY MARKET 37
FIGURE 15 ASIA-PACIFIC MARKET HOLDS LUCRATIVE GROWTH OPPORTUNITIES 38
FIGURE 16 CONSUMABLES SEGMENT CONTINUES TO LEAD IDD PRODUCTS MARKET 38
FIGURE 17 HOSPITAL LABORATORIES END-USER SEGMENT TO SEE HIGHEST GROWTH RATE FROM 2014—2019 39
FIGURE 18 IDD MARKET: TECHNOLOGICAL EVOLUTION 41
FIGURE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION 42
FIGURE 20 IDD MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
FIGURE 21 STRATEGIC BENCHMARKING: MAJOR PLAYERS ADOPTED ORGANIC GROWTH STRATEGIES TO ENHANCE THEIR PRODUCT PORTFOLIOS 50
FIGURE 22 SUPPLY CHAIN ANALYSIS 53
FIGURE 23 CONSUMABLES EXPECTED TO BE LARGEST AND FASTEST-GROWING SEGMENT IN FORECAST PERIOD 55
FIGURE 24 NORTH AMERICAN CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE IN THE IDD MARKET (2014 TO 2019) 57
FIGURE 25 APAC INSTRUMENTS SEGMENT TO BE THE FASTEST-GROWING SEGMENT IN THE FORECAST PERIOD (2014 TO 2019) 60
FIGURE 26 THE SERVICES & SOFTWARE SEGMENT IN APAC TO BE THE FASTEST-GROWING MARKET IN THE FORECAST PERIOD (2014 TO 2019) 62
FIGURE 27 THE HEPATITIS B APPLICATION SEGMENT IS EXPECTED TO DOMINATE THE IDD MARKET IN THE FORECAST PERIOD 65
FIGURE 28 NORTH AMERICA TO DOMINATE THE HEPATITIS C DIAGNOSTICS SEGMENT IN THE FORECAST PERIOD (2014 TO 2019) 68
FIGURE 29 ASIA-PACIFIC WILL GROW AT THE FASTEST RATE IN THE FORECAST PERIOD 70
FIGURE 30 NORTH AMERICA WILL DOMINATE THE GLOBAL IDD MARKET FOR HPV INFECTION SEGMENT IN 2019 75
FIGURE 31 MRSA INFECTION DIAGNOSTICS SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN APAC 77
FIGURE 32 NORTH AMERICA HOLDS THE LARGEST SHARE OF THE OTHER INFECTIONS DIAGNOSTICS MARKET 79
FIGURE 33 IMMUNODIAGNOSTICS WILL GROW AT THE HIGHEST RATE IN THE NEXT
FIVE YEARS 82
FIGURE 34 NORTH AMERICA WILL CONTINUE TO LEAD IDD MICROSCOPY MARKET 86
FIGURE 35 PCR DIAGNOSTICS EXPECTED TO DOMINATE THE IDD TECHNOLOGY MARKET FOR MOLECULAR DIAGNOSTIC TESTS IN 2014 89
FIGURE 36 NORTH AMERICA EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE IDD MARKET FOR PCR IN 2014 90
FIGURE 37 NORTH AMERICA EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INFECTIOUS DISEASE DIAGNOSTICS INAAT MARKET IN 2014 92
FIGURE 38 ASIA-PACIFIC DNA SEQUENCING MARKET EXPECTED TO BE THE FASTEST GROWING MARKET IN THE FORECAST PERIOD (2014 TO 2019) 95
FIGURE 39 ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTICS MICROARRAYS MARKET TO SHOW LUCRATIVE GROWTH OPPORTUNITIES 97
FIGURE 40 BROAD END-USER BASE OF INFECTIOUS DISEASE DIAGNOSTICS 102
FIGURE 41 HOSPITAL LABORATORIES SEGMENT TO DOMINATE IDD END-USER MARKET
IN 2014 103
FIGURE 42 HOSPITAL LABORATORIES IN APAC EXPECTED TO DRIVE THE IDD MARKET IN FORECAST PERIOD 104
FIGURE 43 REFERENCE LABORATORIES IN NORTH AMERICA TO COMMAND LARGEST MARKET SHARE IN 2014 106
FIGURE 44 PHYSICIANS’ OFFICE LABORATORIES IN NORTH AMERICA ACCOUNT FOR LARGEST MARKET SHARE IN 2014 108
FIGURE 45 ASIA-PACIFIC EXPECTED TO BE FASTEST-GROWING MARKET FOR POC END-USERS IN FORECAST PERIOD 110
FIGURE 46 GEOGRAPHIC SNAPSHOT (2014): ASIA-PACIFIC IDD MARKET IS EMERGING AS A NEW REVENUE POCKET FOR MANUFACTURERS 113
FIGURE 47 ASIA–PACIFIC: AN ATTRACTIVE DESTINATION FOR ALL PRODUCT CATEGORIES 114
FIGURE 48 NORTH AMERICAN MARKET SNAPSHOT: DEMAND FOR IDD WILL BE DRIVEN BY THE RISING NUMBER OF INFECTIOUS DISEASES 116
FIGURE 49 INAAT AND MICROARRAY EXPECTED TO BE THE FASTEST-GROWING SEGMENTS DURING THE FORECAST PERIOD (2014–2019) 118
FIGURE 50 THE CONSUMABLES SEGMENT TO DOMINATE THE IDD PRODUCT MARKET DURING THE FORECAST PERIOD (2014–2019) 120
FIGURE 51 THE HOSPITAL LABORATORIES END-USER SEGMENT TO DOMINATE THE IDD MARKET IN THE U.S. (2014) 125
FIGURE 52 EUROPEAN MARKET SNAPSHOT: CONSUMABLES SEGMENT TO DOMINATE
THE MARKET 131
FIGURE 53 CONSUMABLES TO BE THE FASTEST-GROWING PRODUCT SEGMENT IN APAC (2014 TO 2019) 139
FIGURE 54 MRSA APPLICATION SEGMENT TO DRIVE THE IDD MARKET IN APAC
(2014 TO 2019) 140
FIGURE 55 ROW MARKET SNAPSHOT: THE HEPATITIS B APPLICATION SEGMENT CONTINUES TO DOMINATE THE MARKET 142
FIGURE 56 PRODUCT INNOVATION AND AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS WERE THE KEY GROWTH STRATEGIES 146
FIGURE 57 GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE,
BY KEY PLAYER, 2013 147
FIGURE 58 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES AND AGREEMENTS, COLLABORATION AND PARTNERSHIPS WERE KEY STRATEGIES 148
FIGURE 59 GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS 162


【レポートのキーワード】

感染症検査試薬、感染症検査キット、感染症診断機器、感染症診断アナライザー、B型肝炎検査、C型肝炎検査、AIDS検査、結核検査、トラコーマクラミジア感染症、淋菌感染症、HPV感染症、MRSA感染症、医療機器

★調査レポート[感染症診断・検査製品の世界市場:感染症検査試薬、検査キット、診断機器、アナライザー] (コード:MAM-MD-3088)販売に関する免責事項を必ずご確認ください。
★調査レポート[感染症診断・検査製品の世界市場:感染症検査試薬、検査キット、診断機器、アナライザー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆